XML 157 R111.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Goodwill and other intangible assets - Detailed Information for Principal Marketed Products (Details) - EUR (€) € in Millions | 12 Months Ended |  |
--- | --- | --- | ---
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | € 24,319 | € 21,640 | € 21,407
Marketed products |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Concentration risk percentage | 96.00% |  |
Other intangible assets | € 16,600 | 12,700 | 11,700
Useful life, intangible assets other than goodwill (in years) | 11 years |  |
Total: principal marketed products |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | € 15,927 | 11,863 | 10,752
Genzyme |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | € 208 | 621 | 1,032
Useful life, intangible assets other than goodwill (in years) | 10 years |  |
Remaining amortisation period of intangible assets material to entity | 2 years |  |
Boehringer Ingelheim Consumer Healthcare |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | € 1,806 | 2,037 | 2,213
Useful life, intangible assets other than goodwill (in years) | 17 years |  |
Remaining amortisation period of intangible assets material to entity | 11 years |  |
Aventis |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | € 43 | 58 | 73
Useful life, intangible assets other than goodwill (in years) | 9 years |  |
Remaining amortisation period of intangible assets material to entity | 11 years |  |
Chattem |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | € 501 | 574 | 593
Useful life, intangible assets other than goodwill (in years) | 23 years |  |
Remaining amortisation period of intangible assets material to entity | 10 years |  |
Protein Sciences |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | € 420 | 498 | 532
Useful life, intangible assets other than goodwill (in years) | 13 years |  |
Remaining amortisation period of intangible assets material to entity | 7 years |  |
Ablynx |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | € 1,220 | 1,357 | 1,494
Useful life, intangible assets other than goodwill (in years) | 14 years |  |
Remaining amortisation period of intangible assets material to entity | 9 years |  |
Bioverativ |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | € 5,152 | 4,836 | 3,065
Useful life, intangible assets other than goodwill (in years) | 14 years |  |
Remaining amortisation period of intangible assets material to entity | 9 years |  |
REZUROCK |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | € 1,580 | 1,702 | 1,750
Useful life, intangible assets other than goodwill (in years) | 12 years |  |
Remaining amortisation period of intangible assets material to entity | 10 years |  |
TZIELD |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | € 2,405 | 0 | 0
Useful life, intangible assets other than goodwill (in years) | 12 years |  |
Remaining amortisation period of intangible assets material to entity | 12 years |  |
BEYFORTUS |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | € 1,870 | 180 | 0
Useful life, intangible assets other than goodwill (in years) | 18 years |  |
Remaining amortisation period of intangible assets material to entity | 17 years |  |
QUNOL |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | € 722 | € 0 | € 0
Useful life, intangible assets other than goodwill (in years) | 10 years |  |
Remaining amortisation period of intangible assets material to entity | 9 years |  |
Gross value | Total: principal marketed products |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | € 66,880 |  |
Gross value | Genzyme |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | 10,279 |  |
Gross value | Boehringer Ingelheim Consumer Healthcare |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | 3,504 |  |
Gross value | Aventis |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | 33,043 |  |
Gross value | Chattem |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | 1,319 |  |
Gross value | Protein Sciences |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | 831 |  |
Gross value | Ablynx |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | 1,966 |  |
Gross value | Bioverativ |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | 8,798 |  |
Gross value | REZUROCK |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | 1,907 |  |
Gross value | TZIELD |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | 2,546 |  |
Gross value | BEYFORTUS |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | 1,946 |  |
Gross value | QUNOL |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | 741 |  |
Accumulated amortization & impairment | Total: principal marketed products |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | (50,953) |  |
Accumulated amortization & impairment | Genzyme |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | (10,071) |  |
Accumulated amortization & impairment | Boehringer Ingelheim Consumer Healthcare |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | (1,698) |  |
Accumulated amortization & impairment | Aventis |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | (33,000) |  |
Accumulated amortization & impairment | Chattem |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | (818) |  |
Accumulated amortization & impairment | Protein Sciences |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | (411) |  |
Accumulated amortization & impairment | Ablynx |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | (746) |  |
Accumulated amortization & impairment | Bioverativ |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | (3,646) |  |
Accumulated amortization & impairment | REZUROCK |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | (327) |  |
Accumulated amortization & impairment | TZIELD |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | (141) |  |
Accumulated amortization & impairment | BEYFORTUS |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | (76) |  |
Accumulated amortization & impairment | QUNOL |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Other intangible assets | € (19) |  |
Bottom of range |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Useful life, intangible assets other than goodwill (in years) | 1 year |  |
Top of range |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |
Useful life, intangible assets other than goodwill (in years) | 25 years |  |

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfIntangibleAssetsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2023-01-01 -Paragraph 118 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard -URIDate 2023-03-23 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 54 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_c&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_IntangibleAssetsOtherThanGoodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The remaining amortisation period of individual intangible assets that are material to the entity’s financial statements. [Refer: Depreciation and amortisation expense] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2023-01-01 -Paragraph 122 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_122_b&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2023-01-01 -Paragraph 118 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_a&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Concentration risk threshold percentage. + References No definition available. + Details
Name: | sny_ConcentrationRiskThresholdPercentage
Namespace Prefix: | sny_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_MarketedProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsGenzymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsAventisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsChattemMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsProteinSciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsAblynxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsBioverativMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsRezurockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsTZIELDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsBeyfortusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsQunolMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |